Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hydralazine and Valproate Added to Chemotherapy for Breast Cancer

This study has been terminated.
Sponsor:
Collaborators:
National Council of Science and Technology, Mexico
Psicofarma S.A. de C.V.
Information provided by:
National Institute of Cancerología
ClinicalTrials.gov Identifier:
NCT00395655
First received: November 1, 2006
Last updated: NA
Last verified: November 2006
History: No changes posted